Carteolol

Carteolol
Clinical data
Trade names	Ocupress
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a601078
License data	US DailyMed: Carteolol;
Routes of; administration	Eye drops
ATC code	C07AA15 (WHO) S01ED05 (WHO);
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	85%
Metabolism	Liver, active with 8-hydrocarteolol
Elimination half-life	6–8 hours
Excretion	Kidney (50–70%)
Identifiers
	IUPAC name (RS)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one;
CAS Number	51781-06-7;
PubChem CID	2583;
IUPHAR/BPS	7142;
DrugBank	DB00521 ;
ChemSpider	2485 ;
UNII	8NF31401XG;
KEGG	D07624 ;
ChEBI	CHEBI:3437 ;
ChEMBL	ChEMBL839 ;
CompTox Dashboard (EPA)	DTXSID3022746 ;
Chemical and physical data
Formula	C16H24N2O3
Molar mass	292.379 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES O=C2Nc1cccc(OCC(O)CNC(C)(C)C)c1CC2;
	InChI InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20) ; Key:LWAFSWPYPHEXKX-UHFFFAOYSA-N ;
	(verify)

Carteolol is a non-selective beta blocker used to treat glaucoma. It is administered in the form of eye drops.^{[citation needed]}

Carteolol was patented in 1972 and approved for medical use in 1980.^[1]

^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 460. ISBN 978-3-527-60749-5.